Literature DB >> 14583578

Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis.

A P Andonopoulos1, N Meimaris, D Daoussis, A Bounas, G Giannopoulos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14583578      PMCID： PMC1754369          DOI： 10.1136/ard.62.11.1116

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  18 in total

Review 1.  New indications for biological therapies.

Authors:  Mariagrazia Catanoso; Nicolò Pipitone; Luca Magnani; Luigi Boiardi; Carlo Salvarani
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

2.  Treatment of refractory temporal arteritis with adalimumab.

Authors:  M Mubashir Ahmed; Eisha Mubashir; Samina Hayat; Marjorie Fowler; Seth Mark Berney
Journal:  Clin Rheumatol       Date:  2006-08-30       Impact factor: 2.980

3.  Infliximab as monotherapy in giant cell arteritis.

Authors:  Imad Uthman; Nadim Kanj; Samir Atweh
Journal:  Clin Rheumatol       Date:  2005-05-18       Impact factor: 2.980

4.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; P Emery; E C Keystone; M H Schiff; P L C M van Riel; M E Weinblatt; M H Weisman
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

Review 5.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

6.  [Giant cell arteritis (arteriitis temporalis, arteriitis cranialis)].

Authors:  D Schmidt; T Ness
Journal:  Ophthalmologe       Date:  2006-04       Impact factor: 1.059

Review 7.  Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management.

Authors:  Jean Schmidt; Kenneth J Warrington
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

Review 8.  Advances in the use of biologic agents for the treatment of systemic vasculitis.

Authors:  Sharon A Chung; Philip Seo
Journal:  Curr Opin Rheumatol       Date:  2009-01       Impact factor: 5.006

Review 9.  Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J W J Bijlsma; M Dougados; P Emery; E C Keystone; L Klareskog; P J Mease
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

Review 10.  The utility of tumour necrosis factor blockade in orphan diseases.

Authors:  E C Keystone
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.